Despite promising phase I/II clinical trial data for DC and peptide-based vaccines targeting tumor-associated antigens MUC1 [101] and telomerase [102], phase III trial outcomes have failed to demonstrate survival benefits over chemotherapy alone for the adjuvant treatment of advanced pancreatic cancer (APC) [103],[104]. The gene discussed is MUC1; the disease is pancreatic neoplasm.